LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Fechado

SetorSaúde

140.29 0.24

Visão Geral

Variação de preço das ações

24h

Atual

Mín

140.04

Máximo

141.94

Indicadores-chave

By Trading Economics

Rendimento

394M

635M

Vendas

215M

2.6B

P/E

Médio do Setor

12.653

35.733

EPS

3.02

Margem de lucro

23.995

Funcionários

7,605

EBITDA

457M

1B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+20.72% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

442M

19B

Abertura anterior

140.05

Fecho anterior

140.29

Sentimento de Notícias

By Acuity

31%

69%

92 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Biogen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de set. de 2025, 09:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 de set. de 2025, 08:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

5 de set. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

5 de set. de 2025, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 de set. de 2025, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 de set. de 2025, 20:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 de set. de 2025, 20:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 de set. de 2025, 20:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 de set. de 2025, 20:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 de set. de 2025, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 de set. de 2025, 20:20 UTC

Ganhos

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 de set. de 2025, 19:23 UTC

Conversa de Mercado

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 de set. de 2025, 19:22 UTC

Ganhos

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 de set. de 2025, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 de set. de 2025, 18:59 UTC

Ganhos

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 de set. de 2025, 18:35 UTC

Conversa de Mercado

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 de set. de 2025, 17:25 UTC

Conversa de Mercado

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 de set. de 2025, 17:20 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 de set. de 2025, 17:17 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de set. de 2025, 17:17 UTC

Conversa de Mercado

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 de set. de 2025, 17:03 UTC

Conversa de Mercado

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 de set. de 2025, 16:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 de set. de 2025, 16:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 de set. de 2025, 16:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 de set. de 2025, 16:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 de set. de 2025, 16:37 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Equities Roundup: Market Talk

5 de set. de 2025, 16:37 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Energy Roundup: Market Talk

5 de set. de 2025, 16:37 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 de set. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

5 de set. de 2025, 16:16 UTC

Ganhos

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Biogen Inc Previsão

Preço-alvo

By TipRanks

20.72% parte superior

Previsão para 12 meses

Média 169.81 USD  20.72%

Máximo 260 USD

Mínimo 118 USD

Com base em 26 analistas de Wall Street que oferecem metas de preço de 12 meses para Biogen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

26 ratings

12

Comprar

14

Manter

0

Vender

Pontuação Técnica

By Trading Central

118.15 / 121.17Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

92 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat